Should be taken on an empty stomach. Best taken on an empty stomach 1 hr before or 2 hr after meals. Ensure adequate fluid intake.
|
|
|
Patients with TPMT and NUDT15 deficiency (e.g. TPMT and NUDT15 intermediate, possible intermediate, and poor metabolisers); previous varicella zoster virus infection, autoimmune conditions (e.g. inflammatory bowel disease). Renal and hepatic impairment. Children. Patient Counselling Avoid excessive exposure to sun and UV light. Monitoring Parameters Consider TPMT genotypic or phenotypic tests, and NUDT15 genotypic tests to identify deficiency prior to treatment initiation. Regularly monitor haematological count (e.g. haemoglobin, platelet, WBC w/ differential) and LFTs (e.g. serum transaminase, alkaline phosphatase and bilirubin levels). Closely monitor haematologic function when changing between formulations. Obtain FBC daily during remission induction.
|
Significant: Rarely, malignancies (e.g. lymphoproliferative disorders, skin cancers, sarcomas, uterine cervical cancer in situ), infections (e.g. severe or atypical infection and viral reactivation), photosensitivity, chromosomal aberrations, tumour lysis syndrome (leading to hyperuricaemia, hyperuricosuria, uric acid nephropathy).
Nervous: Malaise.
GI: Nausea, vomiting, stomatitis, diarrhoea, anorexia.
Dermatologic: Rash.
Potentially Fatal: Myelosuppression (manifested as leucopenia, thrombocytopenia, anaemia), hepatotoxicity (i.e. hepatic necrosis).
|
|
|
Decreases pharmacological effect of anticoagulants (e.g. warfarin, acenocoumarol). May diminish immune response to vaccines. Increased adverse effects w/ xanthine oxidase inhibitors (e.g. allopurinol, oxipurinol, thiopurinol, febuxostat). Increased myelosuppression w/ aminosalicylate derivatives (e.g. mesalazine, olsalazine, sulfasalazine), co-trimoxazole, ribavirin, and other myelosuppressive agents. Increased risk of Epstein-Barr virus-associated lymphoproliferative disorders w/ multiple immunosuppressive agents.
|
|
|
L01BB02 - mercaptopurine ; Belongs to the class of antimetabolites, purine analogues. Used in the treatment of cancer.
|
Sign Out
